Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. - Wikidata - wikimedia - TriplyDB

Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.

Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.

http://www.wikidata.org/entity/Q30437854

about

Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas Hearing improvement after bevacizumab in patients with neurofibromatosis type 2 Phase II study of everolimus in children and adults with neurofibromatosis type 2 and progressive vestibular schwannomas.Recommendations for imaging tumor response in neurofibromatosis clinical trials.Identifying predictors of early growth response and adverse radiation effects of vestibular schwannomas to radiosurgery Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.Optimizing biologically targeted clinical trials for neurofibromatosis.Phase II trial of lapatinib in adult and pediatric patients with neurofibromatosis type 2 and progressive vestibular schwannomas.Tumor pseudoprogression following radiosurgery for vestibular schwannoma A rare retroperitoneal schwannoma in a patient with neurofibromatosis Type 2.Contemporary management of acoustic neuromas.Patterns of relapse and growth kinetics of surgery- and radiation-refractory meningiomas.Pretreatment ADC Values Predict Response to Radiosurgery in Vestibular Schwannomas.Therapeutics for childhood neurofibromatosis type 1 and type 2.Mechanism-based modeling of the clinical effects of bevacizumab and everolimus on vestibular schwannomas of patients with neurofibromatosis type 2.The effect of bevacizumab on vestibular schwannoma tumour size and hearing in patients with neurofibromatosis type 2.Mathematical modeling of efficacy and safety for anticancer drugs clinical development.Vestibular schwannomas: Accuracy of tumor volume estimated by ice cream cone formula using thin-sliced MR images.Bevacizumab decreases vestibular schwannomas growth rate in children and teenagers with neurofibromatosis type 2.Reduced dosage of bevacizumab in treatment of vestibular schwannomas in patients with neurofibromatosis type 2.Neurofibromatosis Type 2.Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2

P2860

Q30359059-550A5916-F30B-4E87-9796-34DC3DECF5B6 Q30387415-3309B03D-B3F1-4AA0-BB8F-8A892956BBB5 Q30422022-0BC5B694-B16F-49F6-8929-528DF8AE2DE6 Q30425757-6B242E98-7C65-4183-B1BA-E245F21E0024 Q30427640-4E995116-8DB2-44E1-B90D-CB5BC18965E8 Q30438136-B7BA9014-1E3A-42EF-93D3-87BB25CFA0EB Q30438898-1C697C63-A3E1-4803-A100-A6B505A4C0BF Q30450038-DCA5A063-974F-4F7C-8588-5C121A1A4140 Q30459606-2C1CFF69-B66C-4257-A3F0-566E86FDE6C3 Q33816942-DC880246-B44F-4802-9849-8B5EB50810E0 Q37873874-D50B4167-04B3-40AD-8AC4-6D8DBD465D94 Q38430591-08A0FD73-9287-40A6-8A09-2FE8ADF2DBD0 Q38837570-CEE51EBB-7C20-46B3-A6D0-85CA4358CE8C Q39716494-6AEBFE2D-B4CB-43AD-BAF5-37C5FBE6F2EF Q39794311-2BC6E31C-C6D8-4502-B7E3-0590771E0A95 Q47424261-CFB5198F-918E-4B80-B164-206134910E20 Q47663303-5F699D9F-F194-492D-BFE5-F58EA26766C7 Q50041718-7CA96177-6BDD-452A-BEA3-5BC34FC7A78D Q50352494-A98D1C47-CA6B-4701-8178-E72896E52B78 Q50352841-79D179E5-B7A5-4D01-A0F4-3BE5734AF2C2 Q54191697-79CBE43C-2442-452A-8183-42A9FB59A494 Q57266579-800BE1C1-E387-40F7-8E87-0ADBD2855A5E

P2860

Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.

http://www.wikidata.org/entity/Q30437854

description

2009 nî lūn-bûn

@nan

2009 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

Suggested response criteria fo ...... related vestibular schwannoma.

@ast

Suggested response criteria fo ...... related vestibular schwannoma.

@en

type

label

Suggested response criteria fo ...... related vestibular schwannoma.

@ast

Suggested response criteria fo ...... related vestibular schwannoma.

@en

prefLabel

Suggested response criteria fo ...... related vestibular schwannoma.

@ast

Suggested response criteria fo ...... related vestibular schwannoma.

@en

P1433

Q30437854-7841F33A-E101-4C74-8F46-0C57F0B99DFA

P1476

Q30437854-05FBCC23-16F5-400F-B1BF-E074D524D28F

P2093

Q30437854-03B5E6E7-03AF-48AA-9241-080347A8100A

Q30437854-0A740282-5B1A-44CE-9218-BBBF2DBFB65F

Q30437854-18CEAF03-6855-4E13-B28C-1D6B07308648

Q30437854-264429D3-D5E1-4A68-9E00-8A0CFF4C836D

Q30437854-9F18D2A0-371B-4AA2-858D-305B55E7AA6C

Q30437854-A11E285E-FCAB-4CB8-9025-DADB17E28A5C

Q30437854-B11B0BF1-C217-4175-806E-B2BFE7BF9476

Q30437854-B540314A-2CF5-42A2-A895-58635BEDDA67

Q30437854-F09F6D89-8871-4680-90F1-66493BFFB549

Q30437854-FAFEC59F-CF67-4D79-BB4E-5F1684E0F687

P2860

Q30437854-010890C0-F9AF-455B-97E0-A4CB0DB4626A

Q30437854-01D51C96-0561-4143-91B8-306BA221B4F1

Q30437854-02F5BA1D-7668-4A5F-A516-260F282724DD

Q30437854-035AE61C-C251-4D5C-B516-6982FBEF79A7

Q30437854-04FC2810-F8FE-4854-A7A0-B7B4E747680B

Q30437854-05E47550-2924-4116-94C3-665346809662

Q30437854-05ED592D-6488-4F65-9C71-C8987C768D10

Q30437854-06D2DB88-3813-4A48-9976-B31127164875

Q30437854-09BC0E47-E21A-4B32-9A50-E00AA5F5E07B

Q30437854-0A7CA61D-5B3F-4A6F-B69E-ED07A346E49C

P2888

Q30437854-60E7DBD6-DE39-40E3-823E-153F677F49C2

P304

Q30437854-F355B054-026E-4774-B42B-9982609D8226

P31

Q30437854-F608E779-D991-4CA5-9166-2C595217F666

P356

Q30437854-CA86D4C4-5497-4A83-9C5F-B6E040DE3E35

P433

Q30437854-93D5F4BE-C281-478F-A10D-84E783BCB2D1

P478

Q30437854-1ECC36C9-7F02-4EF7-ABFE-33CCECC07C06

P577

Q30437854-D437FB2F-06DF-4668-AD59-AC3884EAD1CD

P6179

Q30437854-D30FBBEA-D869-476E-9FC9-F7A7B63F210C

P698

Q30437854-2C0DC5D4-24B6-4CAA-9027-C6F05F21308F

P932

Q30437854-C38D67EA-455C-4140-BF82-DCCA5F6DF593

P356

S11060-009-9867-7

P1433

Journal of Neuro-Oncology

P1476

Suggested response criteria fo ...... related vestibular schwannoma.

@en

P2093

A Gregory Sorensen

http://www.w3.org/2001/XMLSchema#string

Chris Halpin

http://www.w3.org/2001/XMLSchema#string

D Bradley Welling

http://www.w3.org/2001/XMLSchema#string

Fred G Barker

http://www.w3.org/2001/XMLSchema#string

Gordon J Harris

http://www.w3.org/2001/XMLSchema#string

Jaishri O Blakeley

http://www.w3.org/2001/XMLSchema#string

Jay S Loeffler

http://www.w3.org/2001/XMLSchema#string

Michael J McKenna

http://www.w3.org/2001/XMLSchema#string

Scott R Plotkin

http://www.w3.org/2001/XMLSchema#string

Susan M Chang

http://www.w3.org/2001/XMLSchema#string

P2860

Steroids for idiopathic sudden sensorineural hearing loss

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Reporting results of cancer treatment

The relationship between changes in self-rated quality of life after cochlear implantation and changes in individual complaints.

Assessment of imaging studies used with radiosurgery: a volumetric algorithm and an estimation of its error. Technical note.

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Methodological issues in longitudinal studies: vestibular schwannoma growth rates in neurofibromatosis 2.

A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity.

Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis

Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression.

P2888

s11060-009-9867-7

P304

61-77

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S11060-009-9867-7

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

93

http://www.w3.org/2001/XMLSchema#string

P577

2009-05-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1024772214

http://www.w3.org/2001/XMLSchema#string

P698

19430883

http://www.w3.org/2001/XMLSchema#string

P932

4036446

http://www.w3.org/2001/XMLSchema#string